Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | P2RX7 | Q99572 | 6/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.34 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.34 |
| ▸ | DAO | P14920 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | CX3CR1 | P49238 | 1/20 | 0.34 |
| ▸ | IL1B | P01584 | 4/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30314317 | 1.00 | LMNA (0.39) | LMNAP2RX7ADORA2AADORA2BDAO | |
| SCHEMBL30314375 | 0.89 | LMNA (0.41) | LMNAADORA2AADORA2BDAOALDH1A1 | |
| SCHEMBL20548415 | 0.89 | LMNA (0.41) | LMNAADORA2AADORA2BDAOALDH1A1 | |
| SCHEMBL20551982 | 0.84 | ALDH1A1 (0.40) | LMNAALDH1A1 | |
| SCHEMBL30314273 | 0.84 | ALDH1A1 (0.40) | LMNAALDH1A1 | |
| SCHEMBL29195769 | 0.83 | P2RX7 (0.39) | LMNAP2RX7ADORA2AADORA2BALDH1A1 | |
| SCHEMBL20548418 | 0.82 | P2RX7 (0.58) | LMNAP2RX7ADORA2AADORA2BALDH1A1 | |
| SCHEMBL29195810 | 0.82 | P2RX7 (0.44) | LMNAP2RX7ADORA2AADORA2BALDH1A1 | |
| SCHEMBL30314325 | 0.82 | P2RX7 (0.58) | LMNAP2RX7ADORA2AADORA2BALDH1A1 | |
| SCHEMBL29195800 | 0.81 | P2RX7 (0.40) | LMNAP2RX7ADORA2AADORA2BALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110770214-B | Heterocyclic P2X7 antagonists | 布雷耶疗法有限公司 | 2024-03-29 | — | — | CN | claimed |
| EP-3619200-A1 | HETEROCYCLIC P2X7 ANTAGONISTS | AXXAM S.p.A. (IT) | 2020-03-11 | — | — | EP | claimed |
| US-20200055831-A1 | HETEROCYCLIC P2X7 ANTAGONISTS | BREYE THERAPEUTICS APS (DK) | 2020-02-20 | — | — | US | claimed |
| CN-110770214-A | Heterocyclic P2X7 antagonists | 阿克萨姆股份公司 | 2020-02-07 | — | — | CN | claimed |
| WO-2018202694-A1 | HETEROCYCLIC P2X7 ANTAGONISTS | AXXAM S.P.A. (IT) | 2018-11-08 | — | — | WO | claimed |
| EP-3398941-A1 | HETEROCYCLIC P2X7 ANTAGONISTS | AXXAM S.p.A. (IT) | 2018-11-07 | — | — | EP | claimed |
| US-11623919-B2 | Heterocyclic P2X7 antagonists | BREYE THERAPEUTICS APS (DK) | 2023-04-11 | — | — | US | disclosed |
| US-20200055831-A1 | HETEROCYCLIC P2X7 ANTAGONISTS | BREYE THERAPEUTICS APS (DK) | 2020-02-20 | — | — | US | disclosed |
| US-20200055831-A1 | HETEROCYCLIC P2X7 ANTAGONISTS | BREYE THERAPEUTICS APS (DK) | 2020-02-20 | — | — | US | disclosed |
| EP-3398941-A1 | HETEROCYCLIC P2X7 ANTAGONISTS | AXXAM S.p.A. (IT) | 2018-11-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200055831-A1 | HETEROCYCLIC P2X7 ANTAGONISTS | P2RY1, P2RX1, P2RX3 | LMNA 2079/4885P2RX7 4/4885ADORA2A 29/4885 |
| US-11623919-B2 | Heterocyclic P2X7 antagonists | P2RY1, P2RX1, P2RX3 | LMNA 2079/4885P2RX7 4/4885ADORA2A 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.